Beta-blockers and cardiovascular outcomes in dialysis patients: A cohort study in Ontario, Canada

Nephrology Dialysis Transplantation

Volumn 27, Issue 4, 2012, Pages 1591-1598

  Kitchlu, Abhijat ^a   Clemens, Kristin ^a   Gomes, Tara ^b,c   Hackam, Daniel G ^a   Juurlink, David N ^b,c,d   Mamdani, Muhammad ^b,c,d,e   Manno, Michael ^b   Oliver, Matthew J ^c,d   Quinn, Robert R ^f   Suri, Rita S ^a   Wald, Ron ^d,e   Yan, Andrew T ^d,e   Garg, Amit X ^a,b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e ST MICHAEL'S HOSPITAL   (Canada)

^f UNIVERSITY OF CALGARY   (Canada)

Author keywords

adrenergic beta antagonists; cardiovascular disease; renal dialysis

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; CANADA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MEGADOSE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HEMODIALYSIS; HUMAN; KIDNEY DISEASE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PERITONEAL DIALYSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK REDUCTION; STROKE;

ADRENERGIC BETA-ANTAGONISTS; AGED; AGED, 80 AND OVER; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR DISEASES; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY FAILURE, CHRONIC; MALE; ONTARIO; PROGNOSIS; RENAL DIALYSIS; RETROSPECTIVE STUDIES;

EID: 84859368159     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr460     Document Type: Article

References (50)

1. Furgeson SB, Chonchol M. Beta-blockade in chronic dialysis patients. Semin Dial 2008; 21: 43-48
2. Converse RL, Jacobsen TN, Toto RD et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J ofMed 1992; 327: 1912-1918 (Pubitemid 23006966)
3. Bakris GL, Hart P, Ritz E. Beta blockers in the management of chronic kidney disease. Kidney Int 2006; 70: 1905-1913 (Pubitemid 44863377)
4. Wiysonge CSU, Bradley HA, Mayosi B et al. Beta-blockers for hypertension. Cochrane Database Syst Rev 2007; Art. No.: CD002003. DOI: 10.1002/14651858. CD002003.pub2 (Pubitemid 351835436)
5. Wright JM, Musini VM. First-line drugs for hypertension. Cochrane Database Syst Rev 2009; No.: CD001841. DOI: 10.1002/14651858. CD001841.pub2
6. Coca SG, Krumholz HM, Garg AX et al. Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease. JAMA 2006; 296: 1377-1384 (Pubitemid 44427424)
7. Gowdak LHW, Arantes RL, de Paula FJ et al. Underuse of American College of Cardiology/American Heart Association Guidelines in hemodialysis patients. Ren Fail 2007; 29: 559-565 (Pubitemid 47123823)
8. Statistics Canada. Population by Sex and Age Group, by Province and Territory. 2009
9. Ontario Ministry of Finance. Ontario Population Projections Update, 2007
10. von Elm E, Altman DG, Egger M et al. The strengthening of the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 2008; 61: 344-349 (Pubitemid 351289042)
11. Tu K, Mamdani MM, Jacka RM et al. The striking effect of the Heart Outcomes Prevention Evaluation (HOPE) on ramipril prescribing in Ontario. CMAJ 2003; 168: 553-557 (Pubitemid 36324091)
12. Mamdani MM, Tu JV. Did the major clinical trials of statins affect prescribing behaviour? CMAJ 2001; 164: 1695-1696 (Pubitemid 32702088)
13. Mamdani MM, Juurlink DN, Lee DS et al. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a populationbased cohort study. Lancet 2004; 363: 1751-1756 (Pubitemid 38698377)
14. Juurlink DN, Mamdani MM, Lee DS et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004; 351: 543-551 (Pubitemid 39025171)
15. Juurlink D, Mamdani MM, Kopp A et al. Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA 2003; 289: 1652-1658 (Pubitemid 37430270)
16. Austin PC, Mamdani MM, Tu K et al. Prescriptions for estrogen replacement therapy in Ontario before and after publication of the Women's Health Initiative Study. JAMA 2003; 289: 3241-3242 (Pubitemid 37430074)
17. Alter D, NC, Austin P et al. Effects of socioeconomic status on access to invasive cardiac procedures and on mortality after acute myocardial infarction. N Engl J Med 1999; 341: 1359-1367 (Pubitemid 29503576)
18. Tepel M, Hopfenmueller W, Scholze A et al. Effect of amlodipine on cardiovascular events in hypertensive haemodialysis patients. Nephrol Dial Transplant 2008; 23: 3605-3612
19. Smith SC Jr, Allen J, Blair SN et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006; 113: 2363-2372 (Pubitemid 43947981)
20. Waikar SS, Wald R, Chertow GM et al. Validity of international classification of diseases, ninth revision, clinical modification codes for acute renal failure. J Am Soc Nephrol 2006; 17: 1688-1694 (Pubitemid 43794671)
21. Williams J, Young W. A summary of studies on the quality of health care administrative databases in Canada. In: Goel V et al. Patterns of Health Care in Ontario. The ICES Practice Atlas. Ottawa, Canada: Canadian Medical Association, 1996.
22. Quan H, Parsons GA, Ghali WA. Validity of procedure codes in International Classification of Diseases, 9th revision, clinical modification administrative data. Med Care 2004; 42: 801-809
23. Levy AR, O'Brien BJ, Sellors C et al. Coding accuracy of administrative drug claims in the Ontario Drug Benefit database. Can J Clin Pharmacol 2003; 10: 67-71 (Pubitemid 37028596)
24. Jha P, Deboer D, Sykora K et al. Characteristics and mortality outcomes of thrombolysis trial participants and nonparticipants. J Am Coll Cardiol 1996; 27: 1335-1342 (Pubitemid 26153277)
25. So L, Evans D, Quan H. ICD-10 coding algorithms for defining comorbidities of acute myocardial infarction. BMC Health Serv Res 2006; 6: 161 26.
26. Austin PC. The relative ability of different propensity score methods to balance measured covariates between treated and untreated subjects in observational studies. Med Decis Making 2009; 29: 661-667
27. Charlson ME, Pompei P, Ales KL et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis, 40: 373-383, 1987. (Pubitemid 17055592)
28. Schneeweiss S, Seeger JD, Maclure M et al. Performance of Comorbidity Scores to Control for Confounding in Epidemiologic Studies using Claims Data. Am J Epidemiol 2001; 154: 854-864 (Pubitemid 33000813)
29. Sundararajan V, Henderson T, Perry C et al. New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality. J Clin Epidemiol 2004; 57: 1288-1294 (Pubitemid 40023149)
30. Rochon PA, Tu JV, Anderson GM et al. Rate of heart failure and 1-year survival for older people receiving low-dose [beta]-blocker therapy after myocardial infarction. Lancet 2000; 356: 639-644 (Pubitemid 30627591)
31. Bristow MR, Gilbert EM, Abraham WT et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure-MOCHA Investigators. Circulation 1996; 94: 2807-2816 (Pubitemid 26411745)
32. Beta-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. JAMA 1982; 247: 1707-1714
33. Boissel JP, Leizorovicz A, Picolet H et al. Efficacy of acebutolol after acute myocardial infarction (the APSI trial). The APSI Investigators. Am J Cardiol 1990; 66: 24C-31C (Pubitemid 20342422)
34. Wilcox RG, Roland JM, Banks DC et al. Randomised trial comparing propranolol with atenolol in immediate treatment of suspected myocardial infarction. BMJ 1980; 280: 885-888 (Pubitemid 10105561)
35. Hjalmarson A, Herlitz J, Holmberg S et al. The Goteborg metoprolol trial: effects on mortality and morbidity in acute myocardial infarction. Circulation 1983; 67: I26-I32
36. Compendium of Pharmaceuticals and Specialties. 44th edn. Ottawa, Canada: Canadian Pharmacists Assoication, 2009
37. Nowicki M, Miszczak-Kuban J. Nonselective beta-adrenergic blockade augments fasting hyperkalemia in hemodialysis patients. Nephron 2002; 91: 222-227 (Pubitemid 34621687)
38. Mancia G. Prevention of risk factors: beta-blockade and hypertension. Eur Heart J Suppl 2009; 11: A3-A8
39. Wetmore JB, Shireman TI. The ABCs of cardioprotection in dialysis patients: a systematic review. Am J Kidney Dis 2009; 53: 457-466
40. Cice G, Ferrara L, Di Benedetto A et al. Dilated cardiomyopathy in dialysis patients-beneficial effects of carvedilol: a double-blind, placebo-controlled trial. J Am Coll Cardiol 2001; 37: 407-411
41. Warmack TS, Estes MA, Heldenbrand S et al. Beta-adrenergic antagonists in hypertension: a review of the evidence. Ann Pharmacother 2009; 43: 2031-2043
42. K/DOQI. K/DOQI: clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 2005; 45: S1-S153
43. Cice G, Ferrara L, D'Andrea A et al. Carvedilol increases twoyear survivalin dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J Am Coll Cardiol 2003; 41: 1438-1444 (Pubitemid 36543357)
44. Abbott KC, Trespalacios FC, Agodoa LY et al. Beta-blocker use in long-term dialysis patients: association with hospitalized heart failure and mortality. Arch Intern Med 2004; 164: 2465-2471 (Pubitemid 39628074)
45. Foley RN, Herzog CA, Collins AJ. Blood pressure and long-term mortality in United States hemodialysis patients: USRDS Waves 3 and 4 Study 1. Kidney Int 2002; 62: 1784-1790 (Pubitemid 35286287)
46. Wanner C, Krane V, Marz,Wet al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353: 238-248 (Pubitemid 41058323)
47. Fellstrom BC, Jardine AG, Schmieder RE et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009; 360: 1395-1407
48. Baigent C. "Good News for Kidney Patients: World's Largest Kidney Disease Trial Shows Benefits from Reducing Cholesterol". Press Release. Study of Heart and Renal Protection, Clinical Trial Service Unit and Epidemiological Studies Unit, University of Oxford http://www.ctsu.ox.ac.uk/ ~sharp/press-release.pdf (20 November 2010, date last accessed)
49. Heerspink HJL, Ninomiya T, Zoungas S et al. Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomized controlled trials. Lancet 2009; 393: 1009-1015
50. Agarwal R, Sinha AD. Cardiovascular protection with anti-hypertensive drugs in dialysis patients: a systematic review and meta-analysis. Hypertension 2009; 56: 860-866.